About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
All Older AML Patients and Younger Patients with Adverse Biology Should Receive HMA/Venetoclax Instead of 3+7/Standard Induction
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Daniel Pollyea
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Daniel Pollyea
1,007 views
October 17, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
22:37
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…
Feat.
T. Badar
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
19:10
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
Feat.
H. Kantarjian
12:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…
Feat.
A. Patel
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
12:33
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: AML
Feat.
H. Kantarjian
14:19
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategi…
44:26
University of Colorado Division of Hematology
Novel Therapies in AML and MDS
Feat.
D. Pollyea
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
Feat.
C. Lai
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
Feat.
A. Perl
13:39
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax
Feat.
C. DiNardo
27:28
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
Feat.
A. Patel
32:04
Moffitt Cancer Center
Experts Discuss the Latest Data in Myeloid Diseases
Feat.
A. Kuykendall,
R. Komrokji,
O. Chan,
D. Sallman
15:45
SOHO 2022 Tenth Annual Meeting
SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML
Feat.
M. Konopleva
16:59
MyCancerHaven
Experts Discuss Current and Future Management of AML
Feat.
R. Vij,
N. Daver
18:48
Current Challenges in Hematology
Venetoclax-Based Combinations in Newly Diagnosed AML: A New Golden S…
Feat.
C. DiNardo
06:23
ASH 2022 Conference Coverage
ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Indu…
Feat.
A. Fathi
16:11
MyCancerHaven
Experts Discuss the Use of Targeted Therapies in AML
Feat.
R. Vij,
E. Wang
30:34
UChicago Medicine
2023 Updates in AML and MDS
Feat.
O. Odenike
